Diagnostic Value of KL-6 in ILD

Status Recruiting

Clinical Trial Summary

KL-6 may be a useful biomarker in patients with interstitial lung disease, but there is limited information in non-Asian populations. Therefore, it is necessary to carry out studies in other populations to confirm the diagnostic values of the biomarker and its prognostic implication.

Hypothesis KL-6 may be a useful biomarker in the management of interstitial lung diseases. But it is necessary to know more about its utility in the European population.

Study Objectives:

- To determine the concentration of KL-6 in serum of patients with pulmonary fibrosis at the time of diagnosis compared to patients without pulmonary fibrosis

- Diagnostic yield of KL-6 in patients with pulmonary fibrosis.

- Correlation of KL-6 values with functional and radiological parameters of disease severity at diagnosis.

- Correlation of serum KL-6 values with the evolution of the disease.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Pulmonary Fibrosis

Clinical Trial Details

NCT number	NCT03103191
Study type	Observational [Patient Registry]
Source	Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Contact
Status	Recruiting
Phase
Start date	June 2016
Completion date	December 2023

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04638517` - The TELO-SCOPE Study: Attenuating Telomere Attrition With Danazol. Is There Scope to Dramatically Improve Health Outcomes for Adults and Children With Pulmonary Fibrosis	Phase 2
Recruiting	`NCT05299333` - Comparison of Pulmonary Telerehabilitation and Physical Activity Recommendations in Patients With Post Covid Fibrosis	N/A
Terminated	`NCT04119115` - Integrated Radiographic and Metabolomics Risk Assessment in Patients With Interstitial Lung Diseases
Completed	`NCT01615484` - Ex-vivo Perfusion and Ventilation of Lungs Recovered From Non-Heart-Beating Donors to Assess Transplant Suitability	N/A
Completed	`NCT01417156` - Safety and PK Study of BIBF 1120 in Japanese Patients With IPF: Follow up Study From 1199.31(NCT01136174)	Phase 2
Terminated	`NCT00981747` - Targeting Vascular Reactivity in Idiopathic Pulmonary Fibrosis	Phase 2/Phase 3
Completed	`NCT00001596` - Oral Pirfenidone for the Pulmonary Fibrosis of Hermansky-Pudlak Syndrome	Phase 2
Completed	`NCT00052052` - An Open-Label Study of the Safety and Efficacy of Subcutaneous Recombinant Interferon-Gamma 1b (IFN-Gamma 1b) in Patients With Idiopathic Pulmonary Fibrosis (IPF)	Phase 2
Completed	`NCT01442779` - Clinical Trial of Low Dose Oral Interferon Alpha in Idiopathic Pulmonary Fibrosis	Phase 2
Completed	`NCT00366509` - Role of Helicobacter Pylori and Its Toxins in Lung and Digestive System Diseases
Recruiting	`NCT00001532` - Role of Genetic Factors in the Development of Lung Disease
Recruiting	`NCT04767074` - A Non-pharmacological Cough Control Therapy	N/A
Recruiting	`NCT04864990` - Dyspnea and Idiopathic Pulmonary Fibrosis
Completed	`NCT01961362` - Supplemental Oxygen in Pulmonary Fibrosis
Completed	`NCT01271842` - Long-term Outcome and Lung Capacity in Survivors of ARDS Due to Influenza A (H1N1) v2009 The RESPIFLU Study	N/A
Completed	`NCT00650091` - Evaluating the Effectiveness of Prednisone, Azathioprine, and N-acetylcysteine in Patients With IPF	Phase 3
Active, not recruiting	`NCT00258544` - Microarray Analysis of Gene Expression in Idiopathic Pulmonary Fibrosis (IPF)
Enrolling by invitation	`NCT04930289` - Global Utilization And Registry Database for Improved preservAtion of doNor LUNGs
Completed	`NCT02055222` - Clinical Outcomes and Molecular Phenotypes in Smokers With Parenchymal Lung Disease
Enrolling by invitation	`NCT06327360` - Illness Expectations in Pulmonary Fibrosis